BlackRock’s Elevation Oncology ELEV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-369,048
| Closed | -$135K | – | 5490 |
|
|
2025
Q2 | $135K | Sell |
369,048
-2,808,855
| -88% | -$938K | ﹤0.01% | 4766 |
|
|
2025
Q1 | $823K | Buy |
3,177,903
+14,723
| +0.5% | +$8.4K | ﹤0.01% | 4247 |
|
|
2024
Q4 | $1.78M | Buy |
3,163,180
+258,009
| +9% | +$152K | ﹤0.01% | 4064 |
|
|
2024
Q3 | $1.74M | Buy |
2,905,171
+414,922
| +17% | +$615K | ﹤0.01% | 4037 |
|
|
2024
Q2 | $6.72M | Buy |
2,490,249
+2,318,348
| +1,349% | +$8.73M | ﹤0.01% | 3574 |
|
|
2024
Q1 | $882K | Buy |
171,901
+91,225
| +113% | +$296K | ﹤0.01% | 4229 |
|
|
2023
Q4 | $43.3K | Buy |
80,676
+43,249
| +116% | +$22.9K | ﹤0.01% | 4986 |
|
|
2023
Q3 | $24.8K | Sell |
37,427
-3,978
| -10% | -$4.02K | ﹤0.01% | 5115 |
|
|
2023
Q2 | $62.9K | Buy |
41,405
+8,654
| +26% | +$22.8K | ﹤0.01% | 5023 |
|
|
2023
Q1 | $62.2K | Sell |
32,751
-4,791
| -13% | -$6.18K | ﹤0.01% | 5076 |
|
|
2022
Q4 | $35.7K | Buy |
37,542
+676
| +2% | +$686 | ﹤0.01% | 5288 |
|
|
2022
Q3 | $42K | Sell |
36,866
-845
| -2% | -$1.06K | ﹤0.01% | 5393 |
|
|
2022
Q2 | $52K | Sell |
37,711
-507
| -1% | -$1.27K | ﹤0.01% | 5399 |
|
|
2022
Q1 | $96K | Buy |
38,218
+13,936
| +57% | +$55.9K | ﹤0.01% | 5295 |
|
|
2021
Q4 | $146K | Buy |
24,282
+445
| +2% | +$3.07K | ﹤0.01% | 5175 |
|
|
2021
Q3 | $186K | Buy |
+23,837
| New | +$258K | ﹤0.01% | 5000 |
|
Other funds holding ELEV
BlackRock's ELEV Position: Q3 2025 in Review
BlackRock sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 369,048 shares — an estimated $135K sold.
BlackRock first reported a position in ELEV in Q3 2021 and held it in 16 quarters. The position peaked at $6.72M in Q2 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.
- BlackRock reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
- BlackRock sold 369,048 Elevation Oncology shares in Q3 2025, an estimated $135K.
- BlackRock first reported a position in Elevation Oncology in Q3 2021 and held it in 16 quarters.
- BlackRock's Elevation Oncology position peaked at $6.72M in Q2 2024.
- 1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.
Based on BlackRock's 13F filing for Q3 2025, filed 12 Nov 2025.